Not every patient receiving heparin develops dangerous hyperkalemia. The kidneys are remarkably resilient; in a healthy individual, the contralateral kidney or secondary mechanisms can often compensate for temporary aldosterone blockade. The danger arises when "second hits" are present.
The exact mechanism through which heparin causes hyperkalemia is not fully understood, but several theories have been proposed: heparin cause hyperkalemia
When clinicians reach for heparin—whether for deep vein thrombosis prophylaxis, anticoagulation in atrial fibrillation, or maintaining patency in hemodialysis lines—the primary concerns are usually bleeding risks or the rare but feared heparin-induced thrombocytopenia (HIT). However, lurking in the shadow of these more famous side effects is a subtle metabolic disturbance: In a 70-year-old diabetic with CKD on an
Heparin-induced hyperkalemia is a classic example of a drug side effect that is "dose-dependent" not on the drug’s primary action, but on the patient’s comorbidities. In a healthy 20-year-old, heparin may cause a negligible blip in potassium. In a 70-year-old diabetic with CKD on an ACE inhibitor, it can precipitate a code blue. Without aldosterone activity
Heparin competitively inhibits aldosterone binding to its receptors in the kidney. Essentially, heparin acts as a pharmacological "shield," blocking aldosterone from exerting its effect. Without aldosterone activity, the kidneys retain potassium while excreting sodium.